TY  -  JOUR
AU  -  Mastroianni, Antonio
AU  -  Guadagnino, Giuliana
AU  -  Greco, Sonia
AU  -  Urso, Filippo
AU  -  Mauro, Maria Vittoria
AU  -  Vangeli, Valeria
T1  -  Efficacy of ivabradine in HIV-associated dilated cardiomyopathy
PY  -  2021
Y1  -  2021-04-01
DO  -  10.1701/3584.35690
JO  -  Recenti Progressi in Medicina
JA  -  Recenti Prog Med
VL  -  112
IS  -  4
SP  -  311
EP  -  314
PB  -  Il Pensiero Scientifico Editore
SN  -  2038-1840
Y2  -  2026/04/19
UR  -  http://dx.doi.org/10.1701/3584.35690
N2  -  Summary. Ivabradine is a pure heart rate-lowering drug that acts directly on the sinus node and does not affect atrioventricular or intraventricular conduction times, myocardial contractility or ventricular repolarization. Ivabradine is used in the treatment of adults with New York Heart Association (NYHA) class II-IV chronic heart failure (CHF) with systolic dysfunction, in sinus rhythm, with a heart rate of ≥75 beats per minute (bpm). This report describes the beneficial effect of ivabradine on clinical parameters in a HIV-infected patient with dilated cardiomyopathy presenting with NYHA class III CHF symptoms. Ivabradine improved functional capacity and left ventricular (LV) systolic function in our patient with HIV-related dilated cardiomyopathy and CHF. This report also lists the summaries of potential clinically significant interaction, likely to require additional monitoring, alteration of drug dosage or timing of administration, between ivabradine and antiretroviral drugs.
ER  -